Radiotherapy demand and activity in England 2006-2020

Clinical Oncology

Volumn 25, Issue 9, 2013, Pages 522-530

  Round, C E ^a   Williams, M V ^a   Mee, T ^b   Kirkby, N F ^b   Cooper, T ^c   Hoskin, P ^d   Jena, R ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c Portland House   (United Kingdom)

^d MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Access; Capacity; Demand; Fractionation; Modelling; Radiotherapy

Indexed keywords

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; DECISION TREE; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE NEED; HUMAN; LUNG CANCER; NEOPLASM; PARTIAL MASTECTOMY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; UNITED KINGDOM;

ACCESS; CAPACITY; DEMAND; FRACTIONATION; MODELLING; RADIOTHERAPY;

DOSE FRACTIONATION; ENGLAND; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INCIDENCE; MALE; MODELS, STATISTICAL; NEOPLASM STAGING; NEOPLASMS; RADIOTHERAPY; STOCHASTIC PROCESSES;

EID: 84881553796     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2013.05.005     Document Type: Article

References (34)

1. Bentzen S.M., Herren G., Cottier B., et al. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: ESTRO QUARTS project. Radiother Oncol 2005, 75:355-365.
2. Ash D., Barrett A., Hinks A., Squire C. Re-audit of radiotherapy waiting times (2003). Clin Oncol 2005, 16:387-394.
3. Department of Health. Radiotherapy: developing a world class service for England. Available at: [accessed 30.10.12]. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_074575.
4. Round C., Mee T., Kirkby N., Cooper T., Williams M.V., Jena R. The Malthus programme: developing radiotherapy demand models for breast and prostate cancer at the local, regional and national level. Clin Oncol 2013, 25(9):538-545.
5. Delaney G.P., Jacob S., Featherstone C., Barton M.B. The role of radiotherapy in cancer treatment: estimating optimal utilisation from a review of evidence-based clinical guidelines. Cancer 2005, 104:1129-1137.
6. Zhang-Salomons J., Mackillop W.J. Estimating the lifetime utilization rate of radiotherapy in cancer patients: the multicohort current utilization table (MCUT) method. Comput Methods Programs Biomed 2008, 92:99-108.
7. Denham J.W. How do we bring an acceptable level of radiotherapy services to a dispersed population?. Australas Radiol 1995, 39:171-173.
8. Williams M.V., Drinkwater K.J. Radiotherapy in England in 2007: modelled demand and audited activity. Clin Oncol 2009, 21:575-590.
9. Möller T.R., Brorsson B., Ceberg J., et al. SBU Survey Group. A prospective survey of radiotherapy practice 2001 in Sweden. Acta Oncol 2003, 42:387-410.
10. Barton M.B., Hudson H.M., Delaney G., Gruver P., Liu Z. Patterns of retreatment by radiotherapy. Clin Oncol 2011, 23:10-18.
11. The Scottish Government. Cancer in Scotland: Radiotherapy activity planning 2011-15. Scottish Executive, Edinburgh, 2005. Available at: [accessed 30.10.12]. http://www.scotland.gov.uk/Publications/2006/01/24131719/0.
12. Erridge S.C., Featherstone C., Chalmers R., et al. What will be the radiotherapy machine capacity required for optimal delivery of radiotherapy in Scotland in 2015?. Eur J Cancer 2007, 43:1802-1809.
13. Department of Health. Radiotherapy services in England 2012.Available at: [accessed 06.11.12]. http://www.dh.gov.uk/health/2012/11/radiotherapy-2012/.
14. Jena R., Round C., Mee T., Kirkby N., Hoskin P., Williams M. The Malthus programme - a new tool for estimating radiotherapy demand at a local level. Clin Oncol 2012, 24:1-3.
15. The Malthus programme. Available at: [accessed 02.04.13]. http://www.camradiotherapy.org.uk/malthus.
16. The Malthus programme. Available at: [accessed 02.04.13]. http://www.camradiotherapy.org.uk/malthus/index2.html.
17. National Cancer Services Analysis Team (NatCanSAT). Radiotherapy definitions for the care dataset for radiotherapy. Available at: [accessed 04.04.13]. http://www.natcansat.nhs.uk/rtservices/rtds/home.htm.
18. National Population Projections. Populations projections by age and sex for the United Kingdom, Great Britain and constituent countries. Series PP2 No 26. Office for National Statistics.
19. Cancer Research UK/Association of Cancer Registries CANCERSTATS. Available at: [accessed 18.11.11]. http://info.cancerresearchuk.org/cancerstats.
20. Møller H., Fairley L., Coupland V., et al. The future burden of cancer in England: incidence and numbers of new patients in 2020. Br J Cancer 2007, 96:1484-1488.
21. Taylor F.G., Quirke P., Heald R.J., et al. MERCURY study group. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg 2011, 253:711-719.
22. Tyldesley S., Delaney G., Foroudi F., Barbera L., Kerba M., Mackillop W. Estimating the need for radiotherapy for patients with prostate, breast, and lung cancers: verification of model estimates of need with radiotherapy utilization data from British Columbia. Int J Radiat Oncol Biol Phys 2011, 79:1507-1515.
23. Kerba M., Miao Q., Zhang-Salomons J., Mackillop W. Defining the need for prostate cancer radiotherapy in the general population: a criterion-based benchmarking approach. Clin Oncol 2010, 22:801-809.
24. Jones A.P., Haynes R., Sauerzapf V., Crawford S.M., Zhao H., Forman D. Travel time to hospital and treatment for breast, colon, rectum, lung, ovary, prostate cancer. Eur J Cancer 2008, 44:992-999.
25. Williams M.V., Drinkwater K.J. Geographical variation in radiotherapy services across the UK in 2007 and the effect of deprivation. Clin Oncol 2009, 21:431-440.
26. Wishart G.C., Greenberg D.C., Chou P., Brown C.H., Duffy S., Purushotham A.D. Treatment and survival in breast cancer in the Eastern Region of England. Ann Oncol 2010, 21(2):291-296.
27. Tyldesley S., Zhang-Salomons J., Groome P.A., et al. Association between age and the utilization of radiotherapy in Ontario. Int J Radiat Oncol Biol Phys 2000, 47:469-480.
28. National Institutes of Health State-of-the-Science Conference: Role of active surveillance in the management of men with localized prostate cancer, 5-7 December 2011. Available at: [accessed 02.04.2013]. http://consensus.nih.gov/2011/docs/prostate/ASPC%2520Final%2520Draft%2520Statement.pdf.
29. Ahmed H.U., Arya M., Freeman A., Emberton M. Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?. Lancet Oncol 2012, 13:e509-e517.
30. Dearnaley D., Syndikus I., Sumo G., et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012, 13:43-54.
31. Bentzen S.M., Agrawal R.K., Aird E.G., et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008, 371:1098-1107. START Trialists' Group.
32. Bentzen S.M., Agrawal R.K., Aird E.G., et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008, 9:331-341. START Trialists' Group.
33. Prewett S.L., Aslam S., Williams M.V., Gilligan D. The management of lung cancer: a UK survey of oncologists. Clin Oncol 2012, 24:402-409.
34. The Royal College of Radiologists. Radiotherapy dose-fractionation. The Royal College of Radiologists, London, 2006. Available at: [accessed 30.10.12]. http://www.rcr.ac.uk/publications.aspx%3fPageID%3d149%26PublicationID%3d229.